Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys.

Korver W, Carsillo M, Yuan J, Idamakanti N, Wagoner M, Shi P, Xia CQ, Smithson G, McLean L, Zalevsky J, Fedyk ER.

J Pharmacol Exp Ther. 2019 Aug;370(2):182-196. doi: 10.1124/jpet.119.256602. Epub 2019 May 13.

PMID:
31085699
2.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A.

Cancer Discov. 2019 Jun;9(6):711-721. doi: 10.1158/2159-8290.CD-18-1495. Epub 2019 Apr 15.

PMID:
30988166
3.

NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.

Miyazaki T, Choi IY, Rubas W, Anand NK, Ali C, Evans J, Gursahani H, Hennessy M, Kim G, McWeeney D, Pfeiffer J, Quach P, Gauvin D, Riley TA, Riggs JA, Gogas K, Zalevsky J, Doberstein SK.

J Pharmacol Exp Ther. 2017 Oct;363(1):104-113. doi: 10.1124/jpet.117.243030. Epub 2017 Aug 4.

PMID:
28778859
4.

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.

Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J.

PLoS One. 2017 Jul 5;12(7):e0179431. doi: 10.1371/journal.pone.0179431. eCollection 2017.

5.

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).

Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A, Jones B, Matuszkiewicz J, Miura J, Miyake H, Natala SR, Shi L, Takahashi M, Taylor E, Wyrick C, Yano J, Zalevsky J, Nie Z.

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950. doi: 10.1016/j.bmcl.2016.10.087. Epub 2016 Nov 2.

PMID:
27839918
6.

Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.

Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W.

Clin Cancer Res. 2012 Nov 15;18(22):6296-305. doi: 10.1158/1078-0432.CCR-12-0668. Epub 2012 Sep 26.

7.

Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.

Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE.

J Immunol. 2011 Apr 1;186(7):4223-33. doi: 10.4049/jimmunol.1003412. Epub 2011 Feb 28.

8.

Enhanced antibody half-life improves in vivo activity.

Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR.

Nat Biotechnol. 2010 Feb;28(2):157-9. doi: 10.1038/nbt.1601. Epub 2010 Jan 17.

9.

Engineering fully human monoclonal antibodies from murine variable regions.

Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA.

J Mol Biol. 2010 Mar 12;396(5):1474-90. doi: 10.1016/j.jmb.2009.12.046. Epub 2010 Jan 4.

PMID:
20045416
10.

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.

Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE.

Blood. 2009 Apr 16;113(16):3735-43. doi: 10.1182/blood-2008-10-182048. Epub 2008 Dec 24.

11.

Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection.

Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE.

J Immunol. 2007 Aug 1;179(3):1872-83.

12.

Soluble TNF mediates the transition from pulmonary inflammation to fibrosis.

Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, Kollias G, Aidinis V.

PLoS One. 2006 Dec 27;1:e108.

13.

PanR1, a dominant negative missense allele of the gene encoding TNF-alpha (Tnf), does not impair lymphoid development.

Rutschmann S, Hoebe K, Zalevsky J, Du X, Mann N, Dahiyat BI, Steed P, Beutler B.

J Immunol. 2006 Jun 15;176(12):7525-32.

14.

JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes.

Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, Olefsky JM.

J Biol Chem. 2005 Oct 21;280(42):35361-71. Epub 2005 Aug 5.

15.

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants.

Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, Abbott C, Carmichael D, Chan C, Cherry L, Cheung P, Chirino AJ, Chung HH, Doberstein SK, Eivazi A, Filikov AV, Gao SX, Hubert RS, Hwang M, Hyun L, Kashi S, Kim A, Kim E, Kung J, Martinez SP, Muchhal US, Nguyen DH, O'Brien C, O'Keefe D, Singer K, Vafa O, Vielmetter J, Yoder SC, Dahiyat BI.

Science. 2003 Sep 26;301(5641):1895-8.

16.

Different WASP family proteins stimulate different Arp2/3 complex-dependent actin-nucleating activities.

Zalevsky J, Lempert L, Kranitz H, Mullins RD.

Curr Biol. 2001 Dec 11;11(24):1903-13.

17.

Activation of the Arp2/3 complex by the Listeria acta protein. Acta binds two actin monomers and three subunits of the Arp2/3 complex.

Zalevsky J, Grigorova I, Mullins RD.

J Biol Chem. 2001 Feb 2;276(5):3468-75. Epub 2000 Oct 11.

18.

Transgene-mediated cosuppression in the C. elegans germ line.

Dernburg AF, Zalevsky J, Colaiácovo MP, Villeneuve AM.

Genes Dev. 2000 Jul 1;14(13):1578-83.

19.

beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2.

DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW.

J Cell Biol. 2000 Mar 20;148(6):1267-81.

20.

Supplemental Content

Loading ...
Support Center